Onodera Y, Tanaka M, Sato K
New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd, 16-13 Kitakasai 1-chome, Edogawa-ku, Tokyo 134-8630, Japan.
J Antimicrob Chemother. 2001 Apr;47(4):447-50. doi: 10.1093/jac/47.4.447.
The in vitro inhibitory activities of quinolones against Mycobacterium tuberculosis DNA gyrase were measured. The 50% inhibitory concentrations (IC(50)s) of sitafloxacin (DU-6859a), sparfloxacin, ciprofloxacin and levofloxacin against supercoiling activity of DNA gyrase were 1.67, 4.80, 12.2 and 13.9 mg/L, respectively, and correlated well with their MICs. Two altered proteins of GyrA containing Ala-90Val, or Ala-90Val and Asp-94Gly were also purified and the inhibitory activities of the quinolones ranged from 12 to >83 times weaker than those against the wild-type enzyme. These results suggest that mutations in the corresponding genes confer quinolone resistance.
测定了喹诺酮类药物对结核分枝杆菌DNA旋转酶的体外抑制活性。司帕沙星(DU-6859a)、司氟沙星、环丙沙星和左氧氟沙星对DNA旋转酶超螺旋活性的50%抑制浓度(IC50)分别为1.67、4.80、12.2和13.9mg/L,且与它们的最低抑菌浓度(MIC)相关性良好。还纯化了两种含有Ala-90Val或Ala-90Val和Asp-94Gly的GyrA改变蛋白,喹诺酮类药物对其抑制活性比对野生型酶的抑制活性弱12至83倍以上。这些结果表明相应基因的突变赋予了喹诺酮耐药性。